Coronary microvascular dysfunction (CMD) encompasses several pathogenetic
mechanisms involving coronary microcirculation and plays a major role in determining …

In accordance with the comorbidity-inflammation paradigm, comorbidities and especially
metabolic comorbidities are presumed to drive development and severity of heart failure with …

Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest
challenges facing cardiovascular medicine today. Despite being the most common form of …

Heart failure (HF) is the most rapidly growing cardiovascular health burden worldwide. HF
can be classified into three groups based on the percentage of the ejection fraction (EF) …

Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF
cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF …

Hypertension is the leading risk factor for numerous cardiovascular diseases, including
stroke, coronary artery disease, atrial fibrillation, and peripheral vascular disease. In …

The microtubule network of cardiac muscle cells has unique architectural and biophysical
features to accommodate the demands of the working heart. Advances in live-cell imaging …

Over the past decade, myocardial structure, cardiomyocyte function, and intramyocardial
signaling were shown to be specifically altered in heart failure with preserved ejection …

Background—Characterization of myocardial structural changes in heart failure with
preserved ejection fraction (HFpEF) has been hindered by the limited availability of human …

Objectives The purpose of this study was to investigate the effect of empagliflozin on
diastolic function in a nondiabetic heart failure with reduced ejection fraction (HFrEF) …